CN113461973A - Injectable medical hydrogel - Google Patents

Injectable medical hydrogel Download PDF

Info

Publication number
CN113461973A
CN113461973A CN202110827431.5A CN202110827431A CN113461973A CN 113461973 A CN113461973 A CN 113461973A CN 202110827431 A CN202110827431 A CN 202110827431A CN 113461973 A CN113461973 A CN 113461973A
Authority
CN
China
Prior art keywords
polyethylene glycol
arm
aldehyde
star
terminated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110827431.5A
Other languages
Chinese (zh)
Other versions
CN113461973B (en
Inventor
潘震
闫振坤
陈亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ruining Biotechnology Co ltd
Original Assignee
Shanghai Ruining Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ruining Biotechnology Co ltd filed Critical Shanghai Ruining Biotechnology Co ltd
Priority to CN202110827431.5A priority Critical patent/CN113461973B/en
Publication of CN113461973A publication Critical patent/CN113461973A/en
Application granted granted Critical
Publication of CN113461973B publication Critical patent/CN113461973B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0031—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043—Mixtures of macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/041—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145—Hydrogels or hydrocolloids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
    • C08J3/246—Intercrosslinking of at least two polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2371/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
    • C08J2371/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2471/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
    • C08J2471/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2479/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen, or carbon only, not provided for in groups C08J2461/00 - C08J2477/00
    • C08J2479/02—Polyamines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a medical hydrogel, which is formed by cross-linking aldehyde-terminated star-shaped multi-arm polyethylene glycol, polyethyleneimine and hydrazide-terminated multi-arm polyethylene glycol, wherein the number of arms of the aldehyde-terminated star-shaped multi-arm polyethylene glycol is 2-8, and the single-arm molecular weight is 1000-5000 Da. The invention obtains the injectable hydrogel with rapid gelling and long-term stability by selecting the molar ratio of aldehyde-terminated multi-arm polyethylene glycol, polyethyleneimine and hydrazide-terminated polyethylene glycol.

Description

Injectable medical hydrogel
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to medical hydrogel which can be used as a radiation protection material for fields such as radiotherapy gaskets, vascular embolism, postoperative tissue sealing and leakage prevention, tissue adhesion prevention, tissue filling agents, tissue repair, skin dressing, drug release and the like.
Background
The hydrogel is a soft material containing a large amount of moisture, which is obtained by crosslinking a hydrophilic polymer. The hydrogel has excellent physical and chemical properties and biological characteristics, such as high water content, high elasticity, softness, biocompatibility and the like, and has important application value in the biomedical research fields of drug delivery, tissue engineering and the like. Injectable hydrogels are hydrogels having a certain fluidity, which can be applied by an injection method, exhibit phase transition between sol and gel for external stimuli (changes in temperature, temperature/pH, etc.), are in a liquid state or a semi-solid state having shear thinning properties before being injected into a human body, and can form gel in situ after being injected into the human body, thereby eliminating the need for invasive surgery, effectively avoiding the risk of infection, and reducing the pain of patients. Various injectable PEG hydrogels that have been developed so far include amphiphilic polyester/polypeptide hydrogels in which PEG is a hydrophilic segment, PEG hydrogels prepared by supramolecular interaction, and PEG hydrogels prepared by mild chemical reactions.
Polyethylene glycol (PEG) is a class of nonionic polymers, and is a class of synthetic polymers approved by the U.S. Food and Drug Administration (FDA) for clinical applications in humans due to its good biocompatibility and safety. The PEG can be used as a pharmaceutic adjuvant, and can also be used for modifying (pegylating) the medicine by using the PEG containing the terminal active functional group. The pegylation technology has more advantages, and particularly has the characteristics of prolonging the in vivo circulation time, enhancing the biological activity, avoiding proteolysis and reducing the immune response in the aspect of modifying protein and polypeptide medicaments. Polyethylene glycol conjugates can be prepared by attaching reactive terminal functional groups such as amino, thiol, azide, alkynyl, and aldehyde groups to improve the performance of polyethylene glycol.
The PEG hydrogel is one of ideal materials for tumor radiotherapy gaskets and postoperative tissue sealing, leakage prevention and the like. These application scenarios generally require hydrogels to have a relatively fast gel formation speed and to maintain stability in vivo for a period of time.
CN105963792A discloses a medical hydrogel composition, comprising a first component and a second component, wherein the first component comprises polylysine and polyethyleneimine; the second component comprises one or more of four-arm-polyethylene glycol-succinimide glutarate, four-arm-polyethylene glycol-succinimide succinate and four-arm-polyethylene glycol-succinimide carbonate. When the gel is used, the nucleophilic reagent (polylysine and polyethyleneimine) of the first component and the electrophilic reagent (one or more of four-arm-polyethylene glycol-succinimide glutarate, four-arm-polyethylene glycol-succinimide succinate and four-arm-polyethylene glycol-succinimide carbonate) of the second component are subjected to Michael addition reaction, so that the gel can be rapidly formed and has the excellent property of low swelling. However, the succinimide organic acid ester-terminated polyethylene glycol material has a short half-life in water, is very easily hydrolyzed, requires a special technique to be stored in a powder form at room temperature for a long period of time, and is used within a short time (generally 1 hour) after dissolution, and is low in convenience.
Chinese patent document CN109646723A discloses a medical hydrogel, which is formed by a mixture of aldehyde-terminated multi-arm polyethylene glycol, polyethyleneimine and polylysine. The polylysine serving as a special polyamino compound can form hydrogel with high stability with aldehyde-group-terminated polyethylene glycol, but Schiff base structures formed by amino groups and benzaldehyde groups of most polyamino compounds are easy to hydrolyze, so that the gel stability is poor.
Apostolides et al (Macromolecules 2017,50,5, 2155-2164) disclose the use of hydrazide-terminated polyethylene glycols to react with benzaldehyde-terminated polyethylene glycols to prepare highly stable hydrogels, greatly expanding the variety of polymers that can be used to prepare highly stable hydrogels. However, the reaction speed of the benzaldehyde group and the hydrazide-terminated polyethylene glycol is slow under neutral pH, so that the gel forming speed is slow, and the method is not suitable for a plurality of application scenes needing quick gelation.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides an injectable medical hydrogel, and the hydrogel has higher gelling speed and gel stability through specific system regulation.
The specific technical scheme of the invention is as follows:
a medical hydrogel is prepared by in-situ crosslinking of aldehyde-terminated star-shaped multi-arm polyethylene glycol, hydrazide-terminated star-shaped multi-arm polyethylene glycol and polyamino compounds.
Preferably, the molar ratio of aldehyde group, hydrazide group and amino group in polyethyleneimine is 1: 0.2-5: 0.2 to 5. Further preferably 1: 0.4-2. More preferably 1: 1: 1.
the aldehyde group and the star-shaped multi-arm polyethylene glycol are connected by ester bonds, ether bonds, amido bonds, urethane bonds, imine bonds or urea bonds.
Preferably, the aldehyde group is connected with the star-shaped multi-arm polyethylene glycol through an amido bond or an ester bond, and the hydrazide group is connected with the star-shaped multi-arm polyethylene glycol, the aldehyde-terminated star-shaped multi-arm polyethylene glycol and the hydrazide-terminated star-shaped multi-arm polyethylene glycol can be the same or different, and are preferably the same. The number of arms of the star-shaped multi-arm polyethylene glycol is 2-8, more preferably 4-8, and the single-arm molecular weight is 1000-5000 Da.
The aldehyde group of the medical hydrogel is selected from one or more of aromatic aldehyde group and alkyl aldehyde group, and is preferably benzaldehyde group.
The invention also aims to provide application of the medical hydrogel in the fields of radiotherapy gaskets, vascular embolization, postoperative tissue sealing and leakage prevention, tissue adhesion prevention, tissue fillers, tissue repair, skin dressing, drug release and the like.
The invention also provides a preparation method of the medical hydrogel, which comprises the steps of dissolving the aldehyde-terminated star-shaped multi-arm polyethylene glycol in a buffer solution with the pH value of 4-10 to prepare an aldehyde-terminated star-shaped multi-arm polyethylene glycol solution; dissolving a polyamino compound and multi-arm star polyethylene glycol capped by hydrazide groups in a buffer solution with the pH of 4-10 to prepare a solution; mixing the two to obtain the medical hydrogel.
The above buffer solution of pH4-10 is preferably phosphate or borate buffer solution of pH 4-10.
Preferably, the final concentration of the aldehyde-terminated star-shaped multi-arm polyethylene glycol solution is 2-30% (w/v), preferably 5-20% (w/v); the concentration of the polyamino compound solution is 0.5-20%, preferably 0.5-5% (w/v).
The two-component hydrogel is prepared in a specific application, and comprises a first component containing a nucleophilic functional group and a second component containing an electrophilic functional group, wherein the first component is an aldehyde-terminated hydrophilic compound, the number of arms is not less than two, the hydrophilic compound is aldehyde-terminated star-shaped multi-arm polyethylene glycol, preferably 8-arm, 6-arm and 4-arm polyethylene glycol (single-arm molecular weight is 1000-plus 5000Da), and the aldehyde group is one or more of aromatic aldehyde and alkyl aldehyde, preferably benzaldehyde. The aldehyde groups can be linked to the polymer with stable or hydrolysable chemical bonds.
The second component is a mixed component of hydrazide terminated multi-arm polyethylene glycol and polyethyleneimine.
Figure BDA0003174248690000031
Ester bond connection benzaldehyde end-capped 8-arm polyethylene glycol
Figure BDA0003174248690000032
Ester bond connection benzaldehyde end-capped 6-arm polyethylene glycol
Figure BDA0003174248690000041
Ester bond connection benzaldehyde end-capped 4-arm polyethylene glycol
Figure BDA0003174248690000042
Hydrazide-terminated 8-arm polyethylene glycol
Figure BDA0003174248690000051
Hydrazide-terminated 6-arm polyethylene glycol
Figure BDA0003174248690000052
Hydrazide-terminated 4-arm polyethylene glycol
Figure BDA0003174248690000053
Polyethylene imine
Both of the above components may be provided in the form of an aqueous solution or powder due to the stability of the aldehyde group and the amino group in the aqueous solution. When in use, the two components are respectively dissolved in the buffer solution, and then the components are mixed to obtain the hydrogel. The two components of the hydrogel can be stored in a double syringe respectively, and the two components are sprayed out through a mixing head or injected to a designated position to form gel when in use.
The invention utilizes the aldehyde group at the end of the multi-arm polyethylene glycol, the hydrazide group at the end of the multi-arm polyethylene glycol and the amino group of the polyamino compound to react to generate schiff base so as to generate crosslinking and form the medical injectable gel.
The invention has the advantages that:
in view of the fact that hydrogel formed between aldehyde-terminated polyethylene glycol and hydrazide-terminated polyethylene glycol in the prior art cannot meet the requirement of gel forming speed easily, and aldehyde-terminated polyethylene glycol and amino-terminated polyethylene glycol cannot meet the requirement of high stability easily. Compared with the prior art, the medical hydrogel provided by the invention has the advantages of high gelling speed and higher stability.
According to the invention, the molar ratio between the aldehyde group of the aldehyde-group-terminated star-shaped multi-arm polyethylene glycol and the hydrazide group of the hydrazide-group-terminated star-shaped multi-arm polyethylene glycol and the molar ratio between the aldehyde group and the amino group in polyethyleneimine are selected, so that the hydrogel with high gelling speed and high stability is obtained, and the gelling speed and stability can be further adjusted through the molecular weight and the arm number of the polyethylene glycol.
Detailed Description
The following examples illustrate specific steps of the present invention, but are not intended to limit the invention.
Terms used in the present invention generally have meanings commonly understood by those of ordinary skill in the art, unless otherwise specified.
The invention is described in further detail below with reference to specific examples and data, it being understood that these examples are intended to illustrate the invention and are not intended to limit the scope of the invention in any way.
In the following examples, various procedures and methods not described in detail are conventional methods well known in the art.
The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto.
Example 1 examination of the Effect of polyethyleneimine and hydrazide-terminated polyethylene glycols on gel formation Rate and gel stability
200mg of ester-linked benzaldehyde-terminated 8-arm polyethylene glycol (molecular weight 10kDa, one-arm molecular weight 1250Da) was dissolved in 2mL of a phosphate buffer solution (pH5.6) as a solution A; preparing borax buffer solution (pH9.2) containing 8-arm polyethylene glycol (molecular weight 10kDa, single-arm molecular weight 1250Da) and/or polyethyleneimine (M.W.1.8K) blocked by hydrazide as solution B; and mixing the A, B solution in equal volume to obtain the hydrogel with viscosity.
Formulation of Molar ratio of polyethyleneimine amino, hydrazide group to benzaldehyde group Gel forming time Gel stability
1 0:1:1 45min More than 6 weeks
2 1:0:1 4s Less than 24 hours
3 1:1:1 7s For more than 4 weeks
Experimental results show that the gelling speed of the benzaldehyde-terminated polyethylene glycol and the hydrazide-terminated polyethylene glycol is low (45min) but the stability of the formed gel is high, and the gelling speed of the benzaldehyde-terminated polyethylene glycol and polyethyleneimine is high but the stability of the formed gel is poor. The gel forming speed of the benzaldehyde-terminated polyethylene glycol and the mixed solution of the benzaldehyde-terminated polyethylene glycol is high, and the gel stability is high.
Example 2 the effect of amino-terminated multi-arm star polyethylene glycol and hydrazide-terminated star polyethylene glycol on gel formation time and stability was examined.
200mg of benzaldehyde-terminated star-shaped multi-arm polyethylene glycol connected by an ester bond is dissolved in 2mL of phosphate buffer (pH5.6) to be used as A solution; preparing a borax buffer solution (pH9.2) solution containing hydrazide-terminated or amino-terminated multi-arm polyethylene glycol (the molar ratio of hydrazide groups or amino groups to benzaldehyde groups is 1:1) and polyethyleneimine (M.W.1.8K, and the molar ratio of benzaldehyde to amino groups is 1:1) as a solution B; and mixing the A, B solution in equal volume to obtain the hydrogel with viscosity.
Formulation of Multi-arm polyethylene glycol Terminal group Gel forming time(s) Time of degradation
1 8 arm, 10kDa Hydrazide group 7 For more than 4 weeks
2 8 arm, 20kDa Hydrazide group 25 More than 3 weeks
3 8 arm, 10kDa Amino group 8 Less than 24h
4 8 arm, 20kDa Amino group 28 Less than 24h
The experimental result shows that compared with the polyethylene glycol blocked by the hydrazide group, the gel formed by the polyethylene glycol blocked by the amino group has poor stability, and the chemical bond formed by the benzaldehyde group and the hydrazide group is more stable than the chemical bond formed by the benzaldehyde group and the amino group.
Example 3 examination of the Effect of other polyamino Compounds on gel time relative to polyethyleneimine
200mg of ester-linked benzaldehyde-terminated 8-arm polyethylene glycol (molecular weight 10kDa, one-arm molecular weight 1250Da) was dissolved in 2mL of a phosphate buffer solution (pH5.6) as a solution A; preparing borax buffer solution (pH9.2) solution containing 8-arm polyethylene glycol (molecular weight 10kDa, single-arm molecular weight 1250Da) with hydrazide end capping (molar ratio of hydrazide to benzaldehyde group is 1:1) and polyethyleneimine (M.W.1.8K) or polylysine as solution B; and mixing the A, B solution in equal volume to obtain the hydrogel with viscosity.
Formulation of Class of polyamino compounds Molar ratio of amino group to benzaldehyde group Gel forming time
1 Polyethylene imine 1:1 7s
2 Polylysine 1:1 50s
The experimental results show that the gel forming speed of the hydrogel based on polyethyleneimine is obviously higher than that of polylysine.
Example 4 examination of gel formation speed and gel stability of gels formed by different concentrations of polyethyleneimine
200mg of ester-linked benzaldehyde-terminated 8-arm polyethylene glycol (molecular weight 10kDa, one-arm molecular weight 1250Da) was dissolved in 2mL of a phosphate buffer solution (pH5.6) as a solution A; preparing borax buffer solution (pH9.2) containing 8-arm polyethylene glycol (with molecular weight of 10kDa, single-arm molecular weight of 1250Da and mole ratio of hydrazide group to benzaldehyde group of 1:1) and polyethyleneimine (M.W.1.8K) as solution B; and mixing the A, B solution in equal volume to obtain the hydrogel with viscosity.
Formulation of Molar ratio of polyethyleneimine amino groups to benzaldehyde groups Gel forming time Gel stability
1 0:1 45min More than 6 weeks
2 0.25:1 109s For more than 4 weeks
3 0.5:1 10s For more than 4 weeks
4 1:1 7s For more than 4 weeks
The results show that the use amount of the polyethyleneimine remarkably influences the gelling speed of the hydrogel, when the polyethyleneimine is not added, the gelling time is slow, and when the molar ratio of the amino group to the benzaldehyde group of the polyethyleneimine is more than 0.25:1, the gelling time is remarkably shortened. The amount of polyethyleneimine also affects the stability of the hydrogel, and when polyethyleneimine is not added, the gel stability is highest, and exceeds 6 weeks, and the addition of polyethyleneimine affects the gel stability, but the gel can still be stable within 4 weeks.
Example 5 examination of the Effect of the molar ratio of hydrazide to benzaldehyde group in hydrazide-terminated Star-shaped Multi-armed polyethylene glycol on gel formation speed and gel stability
200mg of ester-linked benzaldehyde-terminated 8-arm polyethylene glycol (molecular weight 10kDa, one-arm molecular weight 1250Da) was dissolved in 2mL of a phosphate buffer solution (pH5.6) as a solution A; preparing borax buffer solution (pH9.2) solution containing 8-arm polyethylene glycol (molecular weight 10kDa, single-arm molecular weight 1250Da) and polyethyleneimine (M.W.1.8K, and the molar ratio of the polyethyleneimine to the benzaldehyde amino group is 1:1) of the hydrazide end capping, and taking the solution as B solution; and mixing the A, B solution in equal volume to obtain the hydrogel with viscosity.
Figure BDA0003174248690000081
The result shows that the molar ratio of the hydrazide to the aldehyde group in the hydrazide-terminated star-shaped multi-arm polyethylene glycol has little influence on the gelling time under the same polyethyleneimine concentration; the mole ratio of the hydrazide group to the aldehyde group obviously influences the gel stability, the gel stability is poor when no hydrazide-terminated polyethylene glycol is added, and the gel stability is obviously improved when the mole ratio of the hydrazide group to the aldehyde group is more than 0.2: 1.
Example 6 examination of the Effect of polyethylene glycols of different molecular weights and arm counts on gel formation Rate and gel stability
200mg of benzaldehyde-terminated star-shaped multi-arm polyethylene glycol connected by an ester bond is dissolved in 2mL of phosphate buffer (pH5.6) to be used as A solution; preparing borax buffer solution (pH9.2) solution containing hydrazide-terminated multi-arm polyethylene glycol (the molar ratio of hydrazide to benzaldehyde group is 1:1) and polyethyleneimine (M.W.1.8K, and the molar ratio of hydrazide to benzaldehyde amino group is 1:1) as solution B; and mixing the A, B solution in equal volume to obtain the hydrogel with viscosity.
Formulation of Number of arms of multi-arm polyethylene glycol Multi-arm polyethylene glycol single-arm molecular weight Gel forming time(s) Time of degradation
1 8 1250 7 For more than 4 weeks
2 8 2500 25 More than 3 weeks
3 6 1250 9 More than 3 weeks
4 6 2500 28 For more than 2 weeks
5 4 1250 12 More than 3 weeks
6 4 2500 40 For more than 2 weeks
The results show that the number of arms and the single-arm molecular weight of the star-shaped multi-arm polyethylene glycol influence the gelling time and the gelling stability of the gel. The number of the arms has certain influence on the gel stability in the gel forming time, and the higher the number of the arms is, the shorter the gel forming time is, and the higher the gel stability is; the single-arm molecular weight has obvious influence on the gelling time and the gel stability, and the higher the single-arm molecular weight is, the longer the gelling time is, and the lower the gel stability is.
Example 7 examination of the influence of the kind of bond between aldehyde group and polyethylene glycol in aldehyde-terminated polyethylene glycol on gel Properties
200mg of benzaldehyde-terminated 8-arm polyethylene glycol (molecular weight: 10kDa) linked by an ester bond or an amide bond was dissolved in 2mL of a phosphate buffer solution (pH5.6) to prepare a solution A; preparing a borax buffer solution (pH9.2) containing 8-arm polyethylene glycol (10kDa, single-arm molecular weight 1250Da) with a hydrazide end capping (the molar ratio of hydrazide to benzaldehyde group is 1:1) and polyethyleneimine (M.W.1.8K) as a B solution; and mixing the A, B solution in equal volume to obtain the hydrogel with viscosity.
Formulation of Connection key type Gel forming time Gel stability
1 Ester bond 7s For more than 4 weeks
2 Amide bond 6s For more than 4 weeks
The result shows that the connection bond between the aldehyde group and the polyethylene glycol has little influence on the performance of the gel, and the prepared hydrogel has the characteristics of high gelling speed and high gel stability.

Claims (10)

1. The medical hydrogel is characterized by being formed by in-situ crosslinking of aldehyde-terminated star-shaped multi-arm polyethylene glycol, hydrazide-terminated star-shaped multi-arm polyethylene glycol and polyethyleneimine.
2. The medical hydrogel according to claim 1, wherein the molar ratio of aldehyde groups to amino groups in the polyethyleneimine is 1: 0.2-5, wherein the molar ratio of aldehyde groups to hydrazide groups is 1: 0.2 to 5.
3. The medical hydrogel according to claim 2, wherein the molar ratio of aldehyde groups, hydrazide groups to amino groups in the polyethyleneimine is 1: 1: 1.
4. the medical hydrogel of claim 1, wherein the aldehyde group is chemically linked to the star-shaped multi-armed polyethylene glycol via an ester, ether, amide, urethane, imine or urea linkage.
5. The medical hydrogel according to claim 4, wherein the aldehyde group is connected with the star-shaped multi-arm polyethylene glycol through an amido bond or an ester bond.
6. The medical hydrogel according to claim 1, wherein the number of arms of the star-shaped multi-arm polyethylene glycol is 2-8, and the molecular weight of a single arm is 1000-.
7. The medical hydrogel of claim 6, wherein the number of arms of said star-shaped multi-arm polyethylene glycol is from 4 to 8.
8. The medical hydrogel according to claim 1, wherein the aldehyde group is selected from one or more of aromatic aldehyde group and alkyl aldehyde group.
9. Use of the medical hydrogel according to any one of claims 1 to 8 in the fields of radiotherapeutic gaskets, vascular embolization, post-operative tissue sealing and leakage prevention, tissue adhesion prevention, tissue bulking agents, tissue repair, skin dressings and drug delivery.
10. The method for preparing the medical hydrogel according to any one of claims 1 to 8, wherein the aldehyde-terminated star-shaped multi-arm polyethylene glycol is dissolved in a buffer solution with a pH of 4 to 10 to prepare an aldehyde-terminated star-shaped multi-arm polyethylene glycol solution; dissolving a polyamino compound and multi-arm star polyethylene glycol capped by hydrazide groups in a buffer solution with the pH of 4-10 to prepare a solution; mixing the two to obtain the medical hydrogel, wherein the final concentration of the aldehyde-terminated star-shaped multi-arm polyethylene glycol solution is 2-30% and w/v, the final concentration of the hydrazide-terminated star-shaped multi-arm polyethylene glycol solution is 2-30% and w/v, and the concentration of the polyamino compound solution is 0.5-20% and w/v.
CN202110827431.5A 2021-07-21 2021-07-21 Injectable medical hydrogel Active CN113461973B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110827431.5A CN113461973B (en) 2021-07-21 2021-07-21 Injectable medical hydrogel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110827431.5A CN113461973B (en) 2021-07-21 2021-07-21 Injectable medical hydrogel

Publications (2)

Publication Number Publication Date
CN113461973A true CN113461973A (en) 2021-10-01
CN113461973B CN113461973B (en) 2023-04-07

Family

ID=77881743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110827431.5A Active CN113461973B (en) 2021-07-21 2021-07-21 Injectable medical hydrogel

Country Status (1)

Country Link
CN (1) CN113461973B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108478867A (en) * 2018-03-13 2018-09-04 中山大学 Injectable macromolecule hydrogel, preparation method based on acylhydrazone key and macromolecule hydrogel injection
CN108498847A (en) * 2018-03-13 2018-09-07 中山大学 Macromolecule hydrogel, preparation method based on acylhydrazone key and skin histology adhesive
CN109646723A (en) * 2019-02-02 2019-04-19 上海瑞凝生物科技有限公司 Medical aquogel with Study On The Radioprotective
CN109939065A (en) * 2018-08-10 2019-06-28 上海瑞凝生物科技有限公司 Medical aquogel
CN111440334A (en) * 2020-05-26 2020-07-24 中国科学院长春应用化学研究所 Injectable hyaluronic acid-based hydrogel and preparation method thereof
CN112225912A (en) * 2020-10-19 2021-01-15 上海瑞凝生物科技有限公司 Degradable medical hydrogel

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108478867A (en) * 2018-03-13 2018-09-04 中山大学 Injectable macromolecule hydrogel, preparation method based on acylhydrazone key and macromolecule hydrogel injection
CN108498847A (en) * 2018-03-13 2018-09-07 中山大学 Macromolecule hydrogel, preparation method based on acylhydrazone key and skin histology adhesive
CN109939065A (en) * 2018-08-10 2019-06-28 上海瑞凝生物科技有限公司 Medical aquogel
CN109646723A (en) * 2019-02-02 2019-04-19 上海瑞凝生物科技有限公司 Medical aquogel with Study On The Radioprotective
CN111440334A (en) * 2020-05-26 2020-07-24 中国科学院长春应用化学研究所 Injectable hyaluronic acid-based hydrogel and preparation method thereof
CN112225912A (en) * 2020-10-19 2021-01-15 上海瑞凝生物科技有限公司 Degradable medical hydrogel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEMETRIS E. APOSTOLIDES等: ""Dynamic Covalent Star Poly(ethylene glycol) Model Hydrogels: A New Platform for Mechanically Robust, Multifunctional Materials"", 《MACROMOLECULES》 *

Also Published As

Publication number Publication date
CN113461973B (en) 2023-04-07

Similar Documents

Publication Publication Date Title
CN109939065B (en) Medical hydrogel
CN109646723B (en) Medical hydrogel with radiation protection effect
CN112225912B (en) Degradable medical hydrogel
EP2214731B1 (en) Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
JP3094074B2 (en) Polysaccharide gel composition
EP2416811B1 (en) Hydrogel tissue adhesive having reduced degradation time
US8241609B2 (en) Method for embolization using liquid embolic materials
US8211418B2 (en) Protein-based polymer tissue adhesives for medical use
EP2448604B1 (en) Hydrogel tissue adhesive for medical use
US20140193360A1 (en) Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same
US20100160960A1 (en) Hydrogel tissue adhesive having increased degradation time
JP2004514778A (en) Polyalkylene glycol viscosity enhancing polymer formulation
US20130195789A1 (en) Low swell, long-lived hydrogel sealant
JP2002541923A (en) Rapidly gelling biocompatible polymer composition
CN114316309B (en) Polyethylene glycol-polylysine hydrogel microsphere and preparation method thereof
CN114369354A (en) Injectable hydrogels for vascular embolization
JPH09103479A (en) Medical material and its production
CN113461973B (en) Injectable medical hydrogel
EP2877514A1 (en) Heat-sensitive amphiphilic polyurethane and aqueous solution capable of being injected based on such material
KR20220067417A (en) The manufacturing Method of cross-linked poly-γ-glutamic acid hydrogel
CN117736565A (en) Polyethylene glycol hydrogel capable of being rapidly degraded and application
CN115725088A (en) Medical hydrogel of hyaluronic acid-polyethylene glycol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant